Investigators observed that plasmacytoma variant translocation 1 (PVT1) and caspase‐10 were upregulated while miR‐23a‐3p was downregulated in high glucose‐induced cardiomyocytes. High glucose repressed cardiomyocyte activity and induced cardiomyocyte apoptosis, but this influence was antagonized by PVT1 knockdown or miR‐23a‐3p overexpression.
[Cell Biology International]
Merck announced that the FDA has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
[Merck & Co., Inc.]
6445212 nan items 1 apa default asc 1
With 16 primary blood samples from 13 patients, researchers demonstrated that photodynamic therapy efficiently killed tumor cells without influencing normal lymphocytes in aggressive diseases such as acute adult T cell leukemia/lymphoma.
6445212 G98J3H2D items 1 apa default asc 1
Sando, Y., Matsuoka, K., Sumii, Y., Kondo, T., Ikegawa, S., Sugiura, H., Nakamura, M., Iwamoto, M., Meguri, Y., Asada, N., Ennishi, D., Nishimori, H., Fujii, K., Fujii, N., Utsunomiya, A., Oka, T., & Maeda, Y. (2020). 5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy. Scientific Reports, 10(1), 17237. https://doi.org/10.1038/s41598-020-74174-x Cite
The authors describe the role of allogeneic hematopoietic stem cell transplantation in cutaneous T-cell lymphomas, and summarize the published data and future perspectives in this area.
Between 2009 and 2015, scientists administered 46 CAR T-cell treatments to 43 patients. Patients had relapsed B-cell malignancies of the following types: diffuse large B-cell lymphoma or primary mediastinal B-cell lymphoma, low-grade B-cell lymphoma, or chronic lymphocytic leukemia.
6445218 RW5QDC82 items 1 apa default asc 1
Scientists generated a novel anti-CD19 CAR expressing PD-1/CD28 chimeric switch-receptor. They then conducted a Phase Ib study to evaluate safety and efficacy of CD19-PD-1/CD28-CAR T cells in the treatment of PD-L1+ B-cell lymphoma.
[Clinical Cancer Research]
6445218 KJJHYBZ7 items 1 apa default asc 1
Liu, H., Lei, W., Zhang, C., Yang, C., Wei, J., Guo, Q., Guo, X., Chen, Z., Lu, Y., Young, K. H., Lu, Z., & Qian, W. (2020). CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-20-1457 Cite
Tim-3 was overexpressed in vascular endothelial HMVECs and HUVECs and in vitro assays were used to determine that Tim-3 promoted cell proliferation, migration, invasion and tube formation through activating cyclin D1, Ras homolog gene family member A and vascular endothelial growth factor receptor 2.
Investigators found that IL-33 expression in a large subset of human glioma specimens and murine models correlated with increased tumor-associated macrophages/monocytes/microglia. In addition, nuclear and secreted functions of IL-33 regulated chemokines that collectively recruit and activated circulating and resident innate immune cells creating a pro-tumorigenic environment.
[Proceedings of the National Academy of Sciences of the United States of America]
6445218 2DEVAD4Z items 1 apa default asc 1
Scholz, F., Grau, M., Menzel, L., Graband, A., Zapukhlyak, M., Leutz, A., Janz, M., Lenz, G., Rehm, A., & Höpken, U. E. (2020). The transcription factor C/EBPβ orchestrates dendritic cell maturation and functionality under homeostatic and malignant conditions. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2008883117 Cite
Researchers studied the effect of blocking JAK pathway signaling on CAR T-cell proliferation, anti-tumor activity and cytokine levels in in vitro and in vivo models. They report that itacitinib, a potent, selective JAK1 inhibitor, was able to significantly and dose-dependently reduce levels of multiple cytokines implicated in CRS in several in vitro and in vivo models.
[Clinical Cancer Research]
6445218 FRS4HHGB items 1 apa default asc 1
Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy | Clinical Cancer Research. (n.d.). Retrieved October 5, 2020, from https://clincancerres.aacrjournals.org/content/early/2020/09/30/1078-0432.CCR-20-1739 Cite
Researchers conduct a first-in-human trial of bispecific anti-CD20, anti-CD19 CAR T cells for relapsed, refractory B cell malignancies.
6445218 LP3EH4P8 items 1 apa default asc 1
Shah, N. N., Johnson, B. D., Schneider, D., Zhu, F., Szabo, A., Keever-Taylor, C. A., Krueger, W., Worden, A. A., Kadan, M. J., Yim, S., Cunningham, A., Hamadani, M., Fenske, T. S., Dropulić, B., Orentas, R., & Hari, P. (2020). Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nature Medicine, 1–7. https://doi.org/10.1038/s41591-020-1081-3 Cite
Scientists report BAFF engagement to BAFF receptor elicited both priming and activating signals for NLRP3 inflammasomes in primary B cells and B lymphoma cell lines.
[Cell Death & Disease]
6445218 6RDA545Q items 1 apa default asc 1